Role of Gas6 and TAM Receptors in the Identification of Cardiopulmonary Involvement in Systemic Sclerosis and Scleroderma Spectrum Disorders

Table 2

Comparison of Gas6, sAxl and sMer according to cardiopulmonary involvement.

	ILD			K–W	Post hoc
	No ()	Mild ()	Severe ()
Gas6 (ng/ml)	23.4 [18.8-28.1]	25.8 [19.5-32.1]	16.6 [15.0-22.1]	6.12,	No vs mild; Mild vs severe
sAxl (ng/ml)	21.6 [18.1-28.4]	24.6 [20.1-32.5]	15.5 [14.9-22.4]	5.73,	n.s.
sMer (ng/ml)	12.9 [8.5-16.0]	12.3 [8.1-16.6]	7.4 [5.4-17.1]	n.s.	n.s.
	PH			K–W	Post hoc
	No ()	CTD-PAH ()	Other PH ()
Gas6 (ng/ml)	23.3 [18.5-28.1]	24.9 [18.8-33.9]	23.5 [23.3-31.9]	n.s.	n.s.
sAxl (ng/ml)	22.1 [18.2-30.1]	24.8 [20.0-28.2]	21.1 [15.6-23.3]	n.s.	n.s.
sMer (ng/ml)	12.4 [8.0-15.8]	18.6 [11.7-20.3]	9.6 [7.4-12.5]	6.44,	No vs CTD-PAH

Abbreviations: ILD: interstitial lung disease; CTD-PAH: connective tissue disease-related pulmonary arterial hypertension; PH: pulmonary hypertension; K–W, Kruskal–Wallis analysis of variance.